Related Experiment Video
Updated: Aug 20, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell
Cathleen Cover1, Peter Fickert, Tamara R Knight
1Liver Research Institute, University of Arizona, Tucson, Arizona 85737, USA.
Abstract:
DNA fragmentation in hepatocytes occurs early after acetaminophen (AAP) overdose in mice. DNA strandbreaks can induce excessive activation of poly(ADP-ribose) polymerases (PARP), which may lead to oncotic necrosis. Based on controversial findings with chemical PARP inhibitors, the role of PARP-1 activation in AAP hepatotoxicity remains unclear. To investigate PARP-1 activation and evaluate a pathophysiological role of PARP-1, we used both PARP inhibitors (3-aminobenzamide; 5-aminoisoquinolinone) and PARP gene knockout mice (PARP-/-). Treatment of C3Heb/FeJ mice with 300 mg/kg AAP resulted in DNA fragmentation and alanine aminotransferase (ALT) release as early as 3 h, with further increase of these parameters up to 12 h. Few nuclei of hepatocytes stained positive for poly-ADP-ribosylated nuclear proteins (PAR) as indicator for PARP-1 activation at 4.5 h. However, the number of PAR-positive cells and staining intensity increased substantially at 6 and 12 h. Pretreatment with 500 mg/kg 3-aminobenzamide before AAP attenuated hepatic glutathione depletion and completely eliminated DNA fragmentation and liver injury. Delayed treatment several hours after AAP was still partially protective. On the other hand, liver injury was not attenuated in PARP-/- mice compared to wild-type animals. Similarly, the specific PARP-1 inhibitor 5-aminoisoquinolinone (5 mg/kg) was not protective. However, 3-aminobenzamide attenuated liver injury in WT and PARP-/- mice. In summary, PARP-1 activation is a consequence of DNA fragmentation after AAP overdose. However, PARP-1 activation is not a relevant event for AAP-induced oncotic necrosis. The protection of 3-aminobenzamide against AAP-induced liver injury was due to reduced metabolic activation and potentially its antioxidant effect but independent of PARP-1 inhibition.
Insights
Acetaminophen overdose causes DNA damage in liver cells, but poly(ADP-ribose) polymerase-1 (PARP-1) activation is not responsible for liver injury. 3-aminobenzamide protects the liver through other mechanisms.
Area of Science:
- Hepatotoxicity and Molecular Mechanisms
- Pharmacology and Toxicology
Background:
- Acetaminophen (AAP) overdose causes DNA fragmentation in hepatocytes, potentially leading to PARP activation and necrosis.
- The specific role of PARP-1 activation in AAP-induced liver injury remains controversial due to conflicting results with chemical inhibitors.
Purpose of the Study:
- To investigate PARP-1 activation following AAP overdose in a mouse model.
- To evaluate the pathophysiological role of PARP-1 in AAP-induced hepatotoxicity using genetic and pharmacological approaches.
Main Methods:
- Mice were treated with AAP (300 mg/kg) and assessed for DNA fragmentation and liver injury markers (ALT).
- PARP-1 activation was measured by detecting poly-ADP-ribosylated proteins (PAR) in hepatocyte nuclei.
- PARP inhibitors (3-aminobenzamide, 5-aminoisoquinolinone) and PARP gene knockout (PARP-/-) mice were used to assess PARP-1's role.
Main Results:
- AAP treatment led to early DNA fragmentation and ALT release, with increased PAR-positive hepatocytes at later time points.
- 3-aminobenzamide pretreatment significantly attenuated liver injury and DNA fragmentation, showing partial protection even with delayed treatment.
- PARP-/- mice and wild-type mice treated with a specific PARP-1 inhibitor (5-aminoisoquinolinone) did not show reduced liver injury, indicating PARP-1 is not critical.
Conclusions:
- PARP-1 activation is a consequence of DNA fragmentation after AAP overdose but not a key driver of oncotic necrosis.
- The protective effect of 3-aminobenzamide against AAP-induced liver injury is independent of PARP-1 inhibition, likely due to reduced metabolic activation or antioxidant properties.
Related Concept Videos
Bioactivation and Tissue Toxicity
Acute Pancreatitis II: Pathophysiology
